BloodPril Reviews: Once-Daily Capsule With a 500 mg Amino Acid Blend Enters the U.S. Cardiovascular Supplement Market

BloodPril announces U.S. availability of a once-daily capsule combining three amino acid forms in a 500 mg proprietary blend. Nitric oxide precursor formula. BloodPril is a once-daily capsule containing a 500 mg proprietary blend of three amino acid forms: L-citrulline DL-malate, L-arginine alpha-ketoglutarate dihydrate and L-arginine HCl. It is available in two-, three- and six-bottle configurations, with 60 capsules per bottle.

LAKELAND, Florida, August 14, 2026 — During August 2021 to August 2023, the prevalence of hypertension among U.S. adults was 47.7 percent, rising to 71.6 percent among adults age 60 and older, according to national survey estimates published by the National Center for Health Statistics (Fryar, C.D., et al., 2024, “Hypertension Prevalence, Awareness, Treatment, and Control Among Adults Age 18 and Older: United States, August 2021–August 2023,” NCHS Data Brief No. 511; cdc.gov). The same report found that just 20.7 percent of adults with hypertension had their blood pressure controlled to below 130/80 mm Hg, and that 51.2 percent were currently taking prescribed medication to lower it.

That control gap has drawn commercial attention to nutritional products positioned around vascular function. Into that category, BloodPril has announced U.S. commercial availability of its once-daily capsule, built on two amino acids studied as precursors in the nitric oxide pathway. This release reports that availability and summarizes the published research on those amino acids, including its limitations and one significant safety finding.

→ Product information, the full supplement facts panel and current package options are published at globenewstoday.com/recommends/bloodpril/

Product Overview

BloodPril is a capsule dietary supplement. The supplement facts panel declares a single proprietary blend weighing 500 mg per capsule, containing L-citrulline DL-malate, L-arginine (alpha-ketoglutarate dihydrate) and L-arginine HCl. The bottle contains 60 capsules at 60 servings per container. Other ingredients are hydroxypropyl methylcellulose (the capsule shell, a plant-derived material rather than gelatin), microcrystalline cellulose and magnesium stearate.

Two characteristics of the panel materially affect what a buyer can evaluate, and both are stated here rather than left for a reader to work out.

First, the blend is proprietary. Under 21 CFR 101.36, U.S. manufacturers may group ingredients and declare only the combined weight, without disclosing how much of each component the blend contains. The practice is legal and widespread. Its consequence here is that the split of the 500 mg between the three named forms is not disclosed and cannot be determined from the label.

Second, all three components are salts or conjugates rather than free amino acids, so the declared weight is not the weight of citrulline or arginine delivered. L-citrulline DL-malate is a citrulline-malate compound in which malic acid accounts for a substantial share of the mass. L-arginine HCl is approximately 82 percent arginine by weight. L-arginine alpha-ketoglutarate pairs two arginine molecules with one alpha-ketoglutarate. The free amino acid content of the 500 mg blend is therefore lower than 500 mg by an amount the label does not specify.

The label directs users to take one capsule daily with an 8 oz. glass of water, and states that up to two capsules daily may be taken. At two capsules, a 60-capsule bottle covers 30 days rather than 60, which buyers should factor into the package configurations described below.

The front panel describes the product as blood pressure support and carries the FDA disclaimer footnote reproduced at the end of this release. It is a dietary supplement, not a medication, and the manufacturer makes no claim that it has been clinically tested as a finished formula.

Statement from the Company

“BloodPril is built on two amino acids with a long research history in vascular function, and we want to be precise about what that history does and does not establish. It means the ingredients have been studied. It does not mean this product has been shown to reproduce the results of those studies, and we make no such claim. We are equally direct about the most important point: nobody should stop, reduce or delay a prescribed blood pressure medication because they are taking this or any supplement. Hypertension is a condition that requires medical management. Anyone considering this product should show the label to their physician first.”

— BloodPrill Product Development Team, BloodPril

Ingredient Research

The following section describes the two amino acids in the BloodPril blend, each accompanied by independently published research. Both are precursors in the nitric oxide pathway; citrulline is converted to arginine in the kidney, and arginine is the substrate from which nitric oxide synthase produces nitric oxide.

Important qualification: all citations below describe research conducted under conditions unaffiliated with BloodPril, in every case at doses substantially higher than the total weight of this blend. Because the blend is proprietary and the components are salts, the amount of each free amino acid in BloodPril is not disclosed and cannot be compared against the amounts used in the research. These citations establish that these amino acids have been studied. They do not constitute clinical evidence that BloodPril produces equivalent outcomes, and no such equivalence is claimed.

L-citrulline (as DL-malate). A non-protein amino acid converted to arginine in the kidney, studied as an indirect route to raising nitric oxide availability. A systematic review and meta-analysis published in Nutrition & Metabolism (Zhu, X., et al., 2019, “Effect of oral L-citrulline on brachial and aortic blood pressure defined by resting status,” doi:10.1186/s12986-019-0415-y) pooled fourteen trials across eight studies and reported reductions in brachial systolic blood pressure of 4.49 mmHg (95% CI −7.33 to −1.65) and brachial diastolic blood pressure of 3.63 mmHg (95% CI −5.83 to −1.43). Aortic systolic pressure fell by 6.76 mmHg, while the reduction in aortic diastolic pressure did not reach statistical significance (p = 0.098). The reviewers stated that the small number of available trials and their limitations meant the findings should be interpreted cautiously and confirmed in larger studies. Trials in this literature have used oral citrulline at 3 to 10 g daily.

Note on a retracted source. A 2018 meta-analysis in the Journal of Human Hypertension reporting larger reductions — 7.54 mmHg systolic and 3.77 mmHg diastolic — has since been retracted by the journal. It is widely quoted in marketing material for citrulline products. It is identified here so that readers encountering those figures elsewhere know their status, and it is not relied on anywhere in this release.

L-arginine (as alpha-ketoglutarate and HCl). The direct substrate for nitric oxide synthase. A systematic review and dose-response meta-analysis published in Advances in Nutrition (Shiraseb, F., et al., 2022, “Effect of L-arginine supplementation on blood pressure in adults,” 13(4):1226–1242, doi:10.1093/advances/nmab155) pooled twenty-two randomized controlled trials and reported reductions in systolic blood pressure of 6.40 mmHg (95% CI −8.74 to −4.05) and diastolic blood pressure of 2.64 mmHg (95% CI −3.94 to −1.40). The dose-response component of that analysis is directly relevant to this product: the effective dosage for systolic blood pressure was identified as 4 g per day or above, and no significant changes were observed at dosages above 9 g per day. The entire BloodPril blend weighs 500 mg, or 1 g at the maximum labeled serving of two capsules, before accounting for the salt fraction. That is well below the threshold identified in the cited analysis.

A Safety Finding Readers Should Know About

One published trial of L-arginine reported a mortality signal, and it is set out here rather than omitted because the population it concerns overlaps with the population interested in a blood pressure supplement.

The Vascular Interaction with Age in Myocardial Infarction trial (Schulman, S.P., et al., 2006, “L-arginine therapy in acute myocardial infarction: the VINTAGE MI randomized clinical trial,” JAMA, 295(1):58–64, doi:10.1001/jama.295.1.58; PMID 16391217) was a randomized, double-blind, placebo-controlled study of 153 patients following a first ST-elevation myocardial infarction. Participants received L-arginine at a target of 9 g daily or placebo alongside standard post-infarction therapy. The trial found no improvement in vascular stiffness or ejection fraction. Six-month mortality was 8.6 percent in the L-arginine group and zero in the placebo group, a difference concentrated in patients age 60 and older, and the data and safety monitoring board terminated the study early. The authors concluded that L-arginine should not be recommended following acute myocardial infarction.

Three qualifications belong with that finding. The dose was 9 g daily, far above anything in this product. Mortality was not the trial’s primary endpoint, and the lead author characterized the observation as hypothesis-generating rather than definitive. And the population was patients recovering from a recent heart attack, not general adults. It is reported here because anyone with established cardiovascular disease evaluating an arginine-containing supplement should be aware that the trial exists and should raise it with their cardiologist.

What the Evidence Base Does and Does Not Show

The published research on both amino acids reports statistically significant average reductions in blood pressure, in the range of roughly 4 to 6 mmHg systolic. Those are real findings from randomized trials, and they are the reason these ingredients appear in products of this kind.

Three things separate those findings from this product. The doses used in the trials are measured in grams; the entire blend here is 500 mg, and less than that in free amino acid content. The arginine dose-response analysis identified 4 g daily as the threshold for a systolic effect, which one or two capsules of this product do not approach. And the proprietary blend means the split between components is unknown, so no comparison against any cited study is possible in either direction.

Ingredient research is a reason to examine a formula. It is not a substitute for testing the formula itself, and no published clinical trial has evaluated BloodPril as sold.

Format and Daily Use

BloodPril is positioned as a nutritional addition to an established cardiovascular care routine, not a replacement for any part of one. Dietary sodium and potassium intake, body weight, physical activity, alcohol consumption, sleep and prescribed medication remain the established determinants of blood pressure, and individual experience varies with all of them.

Blood pressure is a clinical measurement, and hypertension is a diagnosis made and managed by a clinician. Anyone with elevated readings, a hypertension diagnosis, or symptoms such as chest pain, shortness of breath, severe headache or visual disturbance should seek medical evaluation rather than relying on a dietary supplement.

Market Context

The figures below are third-party industry context for the category, not claims by BloodPril about its own commercial performance.

Public health data provides the more meaningful backdrop. The NCHS surveillance report cited at the top of this release (Fryar, C.D., et al., 2024, NCHS Data Brief No. 511) found hypertension prevalence rising sharply with age — 23.4 percent among adults aged 18 to 39, 52.5 percent for ages 40 to 59, and 71.6 percent for those 60 and older — and found that among adults with hypertension, 59.2 percent were aware of the condition while only 20.7 percent had it controlled to below 130/80 mm Hg. That distribution describes the population against which cardiovascular supplements are marketed, and it also indicates that a substantial share of that population has a condition requiring medical management.

Availability and Pricing

BloodPril is sold through the manufacturer’s authorized retail portal. Three package configurations are listed at the time of this release:

• Two bottles at $79 per bottle, $158 total, plus shipping

• Three bottles at $59 per bottle, $177 total, with free U.S. shipping

• Six bottles at $49 per bottle, $294 total, with free U.S. shipping

No single-bottle configuration is offered. The seller describes these as 60-, 90- and 180-day supplies respectively, which assumes the one-capsule serving; at the two-capsule maximum the coverage is half that. All purchases are a one-time charge with no subscription or auto-ship enrollment applied by default. Pricing and promotional terms are set by the seller and subject to change; buyers should confirm current terms at checkout rather than relying on any third-party description, including this one.

Orders are covered by a 60-day money-back guarantee. Buyers should note that the seller’s published terms describe the guarantee as running 60 days from purchase while also referring to a minimum period of use before a refund request; anyone relying on the guarantee should confirm the exact conditions with the seller in writing before ordering, and should retain their order confirmation and return instructions.

→ Current package options, pricing and guarantee terms are listed at globenewstoday.com/recommends/bloodpril/

Quality and Manufacturing

The label states that BloodPril is made in the USA with globally sourced ingredients and that the product has been manufactured in an FDA-registered facility. Under 21 CFR Part 111, dietary supplement manufacturers are required to comply with current Good Manufacturing Practice regulations covering production standards, ingredient identity testing, quality control and accurate labeling. FDA registration of a facility is a filing requirement and is not an FDA endorsement, approval or evaluation of any product made there, and no dietary supplement is approved by the FDA before marketing.

The label does not name the manufacturing facility, and no certificate of analysis or third-party testing record was published on the pages reviewed for this release. Buyers wanting that documentation should request it from the distributor.

Usage Guidance and Safety Information

This section is longer than is typical for a product announcement because the product category warrants it.

BloodPril is intended for adult use. The label directs users to take one capsule daily with an 8 oz. glass of water, states that up to two capsules daily may be taken, and directs users not to exceed the recommended dose. Storage instructions direct buyers to keep the product away from heat, light and humidity and not to use it if the safety seal is damaged or missing. The label states that the product is not for children under 18, and that pregnant or nursing mothers and individuals with a known medical condition should consult a physician before use.

This product is not a substitute for prescribed antihypertensive medication. Stopping or reducing a prescribed blood pressure medication without medical supervision carries a risk of stroke, heart attack and other serious cardiovascular events. No one should adjust a prescribed regimen on the basis of a dietary supplement, and no statement in this release should be read as suggesting otherwise.

Anyone taking medication that lowers blood pressure — including ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers or diuretics — should consult their prescriber before adding an amino acid supplement studied for vascular effects, because of the possibility of additive blood-pressure lowering.

Arginine warrants specific caution alongside nitrates and PDE5 inhibitors such as sildenafil, tadalafil and vardenafil, all of which act on the same nitric oxide pathway and where combined use raises the possibility of excessive hypotension. Anyone taking these medications should speak with a prescriber before use.

Individuals with established cardiovascular disease, a history of myocardial infarction, kidney disease, liver disease or herpes simplex infection should consult a physician before using an arginine-containing product. The VINTAGE MI finding described above is directly relevant to the first two of those groups.

Buyers who monitor their blood pressure at home should continue doing so and should share the readings with their clinician rather than self-interpreting them. Individual results vary. This product is not a substitute for professional medical care and is not a treatment for any medical condition.

Scope of This Announcement

This is a product availability announcement, not a clinical trial report, an efficacy claim or an independent product evaluation. No peer-reviewed trial of the finished BloodPril formula is cited, because the research referenced here concerns individual amino acids rather than the assembled product.

Three points bear on any evaluation. The active ingredients are declared as a proprietary blend of salts, so neither the split between components nor the free amino acid content is disclosed. The doses used in every study cited are measured in grams while the total blend weighs 500 mg. And the refund guarantee applies to the authorized retail portal; third-party listings may not carry the same terms.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.

Affiliate Disclosure: This press release contains a link to a retail partner website through which the distributor may receive compensation if a purchase is made following a referral, disclosed in accordance with the Federal Trade Commission’s guidelines on endorsements and testimonials (16 CFR Part 255). The affiliate relationship does not influence the factual content of this release. No compensation was provided to any researcher, journal or institution cited above, and no citation should be read as an endorsement of this product by its authors or publisher. This release is informational, is based on the product label combined with published research on the individual ingredients, and does not constitute medical advice, diagnosis or treatment. Readers with hypertension, cardiovascular disease or any other medical condition should seek evaluation from a licensed physician.

About BloodPril

BloodPril is a dietary supplement brand distributing a once-daily capsule containing a 500 mg proprietary blend of L-citrulline DL-malate, L-arginine alpha-ketoglutarate dihydrate and L-arginine HCl, supplied in 60-capsule bottles. The product is made in the USA with globally sourced ingredients, manufactured in an FDA-registered facility, and distributed by Blood Pril of Lakeland, Florida, with a 60-day money-back guarantee. BloodPril is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease.

Media Contact

Kevin Shaw, BloodPril Product Support

email: contact@customercs.com

Phone: +1 (855) 889-3137

Address: Blood Pril, 1163, Lakeland, FL 33804, USA

For more press release distribution and guest post services, visit TS Newswire.